SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense volatility and a massive sell-off after Marvell canceled purchase orders linked to Celestial AI, citing a confidentiality breach by management. The community is sharply divided between investors demanding management accountability for the delayed disclosure of this news and those betting on a recovery based on the company's underlying optical technology.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is experiencing intense selling pressure and record-low valuations, leaving investors deeply divided between those viewing the current price as a long-term bargain due to PIF and Uber backing and those fearing further dilution, a potential reverse split, or even bankruptcy. The community is heavily focused on the disconnect between the company's high-performance vehicle technology and its ongoing struggle to sustain share price momentum amid persistent capital burn.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is capturing significant community attention following the successful completion of historic point-to-point air taxi demonstration flights in New York City. Investors are closely monitoring the company's transition from prototype testing to real-world infrastructure integration as they progress through critical FAA certification phases.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as investors react to the company's first revenue growth in 19 quarters and a strategic shift toward an 'Everything Home' marketplace. Community discussions are heavily divided, with some traders highlighting the operational turnaround and bullish technical setups, while skeptics remain focused on the company's past struggles and ongoing cash burn.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing significant momentum and extreme volatility, with the community actively debating whether the move is a sustainable squeeze or a high-risk pump and dump. Traders are closely monitoring key technical levels and volume spikes, with many citing the stock's low float as the primary catalyst for its rapid, multi-day price fluctuations.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science SA is trending due to a breakthrough in molecular farming involving the successful expression of bovine myoglobin in pea seeds, fueling investor excitement and high-volume trading activity. While bullish community members point to the potential for a massive short squeeze given the stock's low float, skeptics are actively debating the company's financials, dilution history, and the sustainability of the price surge.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently driving significant community engagement following a massive earnings beat and upward guidance, with many investors debating whether the stock is a legitimate AI infrastructure play or if it has reached a parabolic, overextended peak. Discussion is heavily focused on the stock's rapid momentum and the contrasting views of bulls citing strong data center growth versus bears pointing to extreme technical indicators like RSI and the likelihood of a sharp correction.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh its potential as an AI infrastructure and robotics player against significant concerns regarding long-term revenue growth, particularly due to Apple's transition away from Qualcomm modems. The stock remains a battleground as the community debates whether its low valuation makes it a compelling turnaround candidate or a value trap amid cooling smartphone demand.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently in focus following positive Phase 3 clinical trial results for its acne treatment in China, which has sparked optimism regarding its licensing strategy and potential U.S. development pathways. Investors are closely monitoring its MASH pipeline and combination therapy efforts, viewing the company as a significantly undervalued acquisition target relative to the billions of dollars in TAM across its therapeutic indications.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as investors react to positive Phase 3 clinical momentum and heavy institutional accumulation from notable funds, fueling speculation regarding a potential buyout or strategic partnership. Community discussion is dominated by the stock's significant move on high volume, with many focusing on the low effective float and the company's lack of debt as potential catalysts for further upward volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX

Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an...

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume  - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above 200-Day Moving Average - Time to Sell...

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research

Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective on the stock in a research report on Monday...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.15	--	--	N/A
Q4 '25	-$1.01	-$1.22	-20.96%	MISSED
Q3 '25	-$0.90	-$1.01	-12.25%	MISSED
Q2 '25	-$0.86	-$0.85	0.68%	BEAT
Q1 '25	-$0.75	-$0.81	-7.29%	MISSED

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CLDX News

CLDXCelldex Therapeutics Inc.